Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

NCT06795503 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

1462

Enrollment

OTHER

Sponsor class

Conditions

Triple-negative Breast Cancer

Interventions

DRUG: Docetaxel plus cyclophosphamide
DRUG: Epirubicin, cyclophosphamide plus paclitaxel

Sponsor

Fudan University